Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.

Zhang H, Luo J, Li Y, Henderson PT, Wang Y, Wachsmann-Hogiu S, Zhao W, Lam KS, Pan CX.

Nanomedicine. 2012 Oct;8(7):1116-24. doi: 10.1016/j.nano.2011.12.004. Epub 2011 Dec 23.


The effect of cantharidins on leukemic stem cells.

Dorn DC, Kou CA, Png KJ, Moore MA.

Int J Cancer. 2009 May 1;124(9):2186-99. doi: 10.1002/ijc.24157.


Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.

Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX.

Nanomedicine (Lond). 2014;9(12):1807-20. doi: 10.2217/nnm.14.44. Epub 2014 Mar 17.


TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Kikushige Y, Miyamoto T.

Int J Hematol. 2013 Dec;98(6):627-33. doi: 10.1007/s12185-013-1433-6. Epub 2013 Sep 18. Review.


Targeting the acute myeloid leukemia stem cells.

Krause A, Luciana M, Krause F, Rego EM.

Anticancer Agents Med Chem. 2010 Feb;10(2):104-10. Review.


Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.

Lu H, Zhou Q, Deshmukh V, Phull H, Ma J, Tardif V, Naik RR, Bouvard C, Zhang Y, Choi S, Lawson BR, Zhu S, Kim CH, Schultz PG.

Angew Chem Int Ed Engl. 2014 Sep 8;53(37):9841-5. doi: 10.1002/anie.201405353. Epub 2014 Jul 23.


Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo.

Scheulen ME, Kramer B, Skorzec M, Reich WK.

Haematol Blood Transfus. 1990;33:122-8. No abstract available.


Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.

Pelosi E, Castelli G, Testa U.

Blood Cells Mol Dis. 2015 Dec;55(4):336-46. doi: 10.1016/j.bcmd.2015.07.015. Epub 2015 Jul 26. Review.


A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.

Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S, Niiro H, Yurino A, Miyawaki K, Takenaka K, Iwasaki H, Akashi K.

Cell Stem Cell. 2015 Sep 3;17(3):341-52. doi: 10.1016/j.stem.2015.07.011. Epub 2015 Aug 13.


Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.

Kikushige Y, Miyamoto T.

Oncology. 2015;89 Suppl 1:28-32. doi: 10.1159/000431062. Epub 2015 Nov 10. Review.


PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity.

Ding Q, Gu R, Liang J, Zhang X, Chen Y.

Med Oncol. 2013 Mar;30(1):395. doi: 10.1007/s12032-012-0395-5. Epub 2013 Jan 19.


Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.

de Figueiredo-Pontes LL, Pintão MC, Oliveira LC, Dalmazzo LF, Jácomo RH, Garcia AB, Falcão RP, Rego EM.

Cytometry B Clin Cytom. 2008 May;74(3):163-8. doi: 10.1002/cyto.b.20403.


A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.

Li Y, Chen K, Zhou Y, Xiao Y, Deng M, Jiang Z, Ye W, Wang X, Wei X, Li J, Liang J, Zheng Z, Yao Y, Wang W, Li P, Xu B.

Curr Cancer Drug Targets. 2015;15(6):493-503.


Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.

Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Gregório AC, Valério-Fernandes Â, Gomes-da-Silva LC, Rosa MS, Moura V, Ramalho-Santos J, Simões S, Moreira JN.

Biomaterials. 2015 Nov;69:76-88. doi: 10.1016/j.biomaterials.2015.08.007. Epub 2015 Aug 6.


CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.

Iwasaki M, Liedtke M, Gentles AJ, Cleary ML.

Cell Stem Cell. 2015 Oct 1;17(4):412-21. doi: 10.1016/j.stem.2015.08.008. Epub 2015 Sep 18.


Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.

Danesh NM, Lavaee P, Ramezani M, Abnous K, Taghdisi SM.

Int J Pharm. 2015 Jul 15;489(1-2):311-7. doi: 10.1016/j.ijpharm.2015.04.072. Epub 2015 Apr 29.


Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P.

Oncotarget. 2012 Dec;3(12):1588-99.


TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y, Akashi K.

Cell Stem Cell. 2010 Dec 3;7(6):708-17. doi: 10.1016/j.stem.2010.11.014.


Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.

Hong Z, Xiao M, Yang Y, Han Z, Cao Y, Li C, Wu Y, Gong Q, Zhou X, Xu D, Meng L, Ma D, Zhou J.

Carcinogenesis. 2011 Oct;32(10):1550-8. doi: 10.1093/carcin/bgr176. Epub 2011 Jul 29.


Supplemental Content

Support Center